West Virginia is currently home to 346 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Morgantown, Charleston, Huntington and Wheeling. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: HER2-negative Breast Cancer
Register for Updates
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
NCT05387837
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: West Virginia University Eye Institute, Morgantown, West Virginia
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Register for Updates
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Wide Neck Bifurcation Intracranial Aneurysms
Register for Updates
Pregabalin vs. Gabapentin on Reducing Opioid Usage
NCT04705480
Recruiting
This is a single-center, randomized, open-label, Phase 4 clinical trial investigating the efficacy of multiple-dose administrations of Pregabalin or Gabapentin in combination with traditional opioid pain medications to decrease the amount of opioid pain medication usage in single-system orthopedic trauma patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2023
Locations: Charleston Area Medical Center"s Level 1 Trauma Center, Charleston, West Virginia
Conditions: Analgesics, Gabapentin, Injuries, Narcotics, Pain, Trauma
Register for Updates
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
NCT05137314
Recruiting
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2022
Locations: WVU, Morgantown, West Virginia
Conditions: Joint Infection
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Edwards Comprehensive Cancer Center, Huntington, West Virginia
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities
NCT05422742
Recruiting
The purpose of this study is to characterize the effect of minocycline microspheres (MM) administered as an adjunct to scaling and rooting planning (SRP) on the subgingival community composition and metatranscriptome functional profile, in comparison to a group treated with SRP only and to periodontally-healthy subjects.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/02/2022
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Periodontitis
Register for Updates
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT05535894
Recruiting
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Shailendra Singh, Morgantown, West Virginia
Conditions: Pancreatic Cancer
Register for Updates
The Effect of Blood on the PC Ratio During Pregnancy
NCT05434845
Recruiting
This study will examine the effect if blood on the the protein to creatine (PC) ratio in pregnant patients by adding blood to urine samples.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
09/06/2022
Locations: Marshall University School of Medicine, Huntington, West Virginia
Conditions: Proteinuria in Pregnancy
Register for Updates
Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
NCT04504188
Recruiting
The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR < 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/12/2022
Locations: CAMC, Charleston, West Virginia
Conditions: Cardiomyopathies, Heart Failure
Register for Updates
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT05013255
Recruiting
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/11/2022
Locations: West Virginia University Cancer Institute, Morgantown, West Virginia
Conditions: Breast Cancer, Muscle Fatigue
Register for Updates